TECTONIC THERAPEUTIC, INC. Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction
TECTONIC THERAPEUTIC, INC. (TECX) reported Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-20.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction · last filed 2025-03-20
- TECTONIC THERAPEUTIC, INC. debt issuance costs incurred during noncash or partial noncash transaction for the quarter ending 2024-12-31 was -$2.52M, a 477.28% decline year-over-year.
- TECTONIC THERAPEUTIC, INC. debt issuance costs incurred during noncash or partial noncash transaction for the quarter ending 2024-09-30 was -$6.25M.
- TECTONIC THERAPEUTIC, INC. debt issuance costs incurred during noncash or partial noncash transaction for the quarter ending 2023-12-31 was $669.00K.
- TECTONIC THERAPEUTIC, INC. debt issuance costs incurred during noncash or partial noncash transaction for the quarter ending 2023-09-30 was $0.00.
- TECTONIC THERAPEUTIC, INC. debt issuance costs incurred during noncash or partial noncash transaction for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- TECTONIC THERAPEUTIC, INC. debt issuance costs incurred during noncash or partial noncash transaction for fiscal 2023 was $669.00K.
| Period end | Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction 3 month | Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction 6 month | Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction 9 month | Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$2.52M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$8.77M derived: sum of 2 quarters · filed 2025-03-20 | $0.00 10-K · filed 2025-03-20 | |
| 2024-09-30 | -$6.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $2.52M 10-Q · filed 2024-11-12 | ||
| 2024-06-30 | $8.77M 10-Q · filed 2024-08-14 | |||
| 2023-12-31 | $669.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $669.00K derived: sum of 2 quarters · filed 2025-03-20 | $669.00K 10-K · filed 2025-03-20 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |